IL2 and hereditary clear cell renal cell carcinoma: Among the numerous interleukins developed for tumor therapy, IL-2, initially called T cell growth factor, holds a significant place as it was the first to receive approval from the U.S. Food and Drug Administration for the treatment of metastatic melanoma and renal cell carcinoma.8